Twist Bioscience and Watchmaker Genomics Announce Partnership to Drive New Applications of High-throughput Genetic Sequencing

Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Watchmaker Genomics to enhance research capabilities in high throughput sequencing applications. Their collaboration aims to facilitate innovations in oncology, inherited disease detection, and liquid biopsy assays. The first product will integrate Watchmaker's high-fidelity amplification technology into Twist's library preparation kits. Both companies focus on delivering exceptional products, optimizing workflows, and improving genomic studies quality through joint development initiatives.

Positive

• Partnership with Watchmaker Genomics enhances research capabilities in genomic applications.
• Integration of high-fidelity amplification technology improves product offerings.
• Focus on innovation and execution aims to streamline workflows and improve data quality.

Negative

• None.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Watchmaker Genomics today announced a broad partnership to enable innovative research across a wide range of high throughput sequencing applications including oncology and tumor profiling, inherited disease detection, liquid biopsy assays, and minimal residual disease monitoring.

In their first product offering together, Twist will leverage Watchmaker’s expertise in enzyme engineering by incorporating the company’s high-fidelity library amplification master mix into Twist’s enzymatic library preparation kit, providing a superior solution that can be accessed from Twist as a single source.

“With our eye squarely on working in service of our customers, this partnership brings together two teams relentlessly focused on innovation and execution to provide superior products,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By pairing superior enzymes with best-in-class DNA, we expect to offer differentiated products that simplify and streamline workflows before putting samples on the sequencer.”

“This is the first in what we believe will be a series of joint product development opportunities between Twist and Watchmaker aimed at driving continued improvement in performance and data quality for high-resolution genomic applications including NGS-based cfDNA and ctDNA studies, single-cell work, low allele somatic variant detection and tumor mutation burden,” said Trey Foskett, co-founder of Watchmaker. “In addition, we look forward to bringing our protein engineering technologies into the product mix to fuel new avenues of research across many disease areas.”

About Watchmaker Genomics

Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines deep domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth genomics applications.

Watchmaker’s product portfolio includes enzymes and kits for next-generation sequencing library preparation, synthetic biology, and molecular diagnostics. Based in Boulder, Colorado, Watchmaker Genomics is co-founded by Trey Foskett, Brian Kudlow, and Stephen Picone. The team brings decades of collective experience building successful life science companies, commercializing novel technologies, and advancing clinical genomics applications. Watchmaker partners directly with innovative life science companies, commercial sequencing providers, and pioneering research labs. For more information, visit http://www.watchmakergenomics.com

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements
This pres

FAQ

What is the new partnership between TWST and Watchmaker Genomics about?

Twist Bioscience (TWST) has partnered with Watchmaker Genomics to enhance research in high throughput sequencing applications.

How will the partnership with Watchmaker Genomics affect TWST's products?

The partnership aims to integrate Watchmaker's high-fidelity library amplification technology into Twist's library preparation kits, improving their product offerings.

What specific applications will the TWST and Watchmaker partnership focus on?

Their collaboration will focus on oncology, inherited disease detection, liquid biopsy assays, and minimal residual disease monitoring.

What is the expected outcome of the partnership for TWST?

The partnership is expected to improve product quality, streamline workflows, and drive innovation in genomic studies.